ADAM Zolmitriptan Shows Efficacy in Acute Treatment of Difficult-to-Treat Migraines
February 1st 2019The acute administration of adhesive dermally applied microarray zolmitriptan (Qytripta, Zosano Pharma) showed an almost uniform benefit across subgroups of patients with severe pain, delayed treatment, nausea, and who were awakening with headache.
Discussing the Risk of Sudden Unexpected Death in Epilepsy With Patients and Caregivers
February 1st 2019The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how broaching the topic of SUDEP has gone from undiscussed to a guideline-mandated practice in epilepsy.
Emerging Evidence Suggestive of Impending Parkinson Disease Pandemic
January 31st 2019The David M. Levy Professor of Neurology and director of the Center for Health and Technology at the University of Rochester Medical Center spoke about the projection for the future and what could be done to mitigate it.
Crenezumab Phase 3 CREAD Trials in Alzheimer Disease Discontinued By Roche
January 30th 2019The Independent Monitoring Committee’s interim analysis suggested that the treatment was unlikely to meet the trials’ primary end point of change from baseline in Clinical Dementia Rating-Sum of Boxes score.
Alemtuzumab and Rituximab Found Safe and Effective in MS Post-Fingolimod Withdrawal
January 30th 2019Data has suggested that patients with multiple sclerosis who have withdrawn from treatment with fingolimod (Gilenya, Novartis) can safely be treated effectively with alemtuzumab (Lemtrada, Sanofi Genzyme) or rituximab (Rituxan, Genentech/Biogen).
SPRINT-MIND Shows No Benefit for Dementia Risk With Intensive Blood Pressure Strategy
January 29th 2019Despite the non-significant differences between groups, a slight trend toward a dementia risk reduction has led to the Alzheimer’s Association providing funds for a follow-up extension trial, dubbed SPRINT-MIND 2.0.
Michael Sperling, MD: The SLATE Trial in Epilepsy
January 29th 2019The Baldwin Keyes Professor of Neurology and director of the Jefferson Comprehensive Epilepsy Center at Thomas Jefferson University spoke about the trial of the Visualase MRI-guided laser ablation system and the unmet needs in epilepsy.
Using Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
January 28th 2019The chief of the Division of Immunotherapy at the Northwestern University Feinberg School of Medicine discussed the results of the randomized clinical trial and the implications of this treatment in clinical practice.
Patient View of Tourette Severity Related More to Functional Impairment Than Tic Noticeability
January 26th 2019The postgraduate epidemiology fellow at the Centers for Disease Control and Prevention discussed the data and what she and her colleagues found in their analyses of children with Tourette syndrome.
Challenges and Excitement in Alzheimer Disease
January 23rd 2019The director of the Center for Neurodegeneration and Translational Neuroscience and director emeritus, Cleveland Clinic Lou Ruvo Center for Brain Health, shared thoughts on his hope for the future of Alzheimer disease, among other topics.
Costantino Iadecola, MD: Cognitive Reserve in Alzheimer Disease
January 23rd 2019The Anne Parrish Titzell Professor of Neurology and Neuroscience at Weill Cornell Medicine’s Feil Family Brain and Mind Research Institute discussed how to make the decision about who will end developing Alzheimer and who will not when amyloid buildup occurs.